BioCryst Pharmaceuticals Inc (BCRX)
Health Care ยท Biological Products, (No Diagnostic Substances)
BioCryst Pharmaceuticals Inc (BCRX) is listed on Nasdaq, where its shares have traded since March 3, 1994. SentiSense covers BioCryst Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Charles Gayer is its chief executive officer. The company reports 435 employees, and its corporate website is www.biocryst.com.
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Latest reported results
BioCryst Pharmaceuticals, Inc. reported revenue of $218.3 million for Q2 FY2026, up 33.6% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 307 institutions reported holding BCRX, with 261.4 million shares worth $2.6 billion in aggregate. The largest reported holders were Vanguard, BlackRock and RA Capital Management. Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter.
More on BCRX
- BCRX sentiment: whether news and social coverage of BioCryst Pharmaceuticals Inc leans bullish or bearish, and the stories driving it.
- BCRX ownership: all 307 reporting institutions, plus insider and congressional trades.
- BCRX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for BioCryst Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does BioCryst Pharmaceuticals Inc do?
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases.
What sector is BCRX in?
SentiSense classifies BioCryst Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does BCRX stock trade?
BioCryst Pharmaceuticals Inc (BCRX) is listed on Nasdaq, where its shares have traded since March 3, 1994.
Who is the CEO of BioCryst Pharmaceuticals Inc?
Charles Gayer is the chief executive officer of BioCryst Pharmaceuticals Inc.